• One online channel to operate and communicate with Igenomix.
• Easy to access your patient reports anytime.
• Live Chat with Igenomix Customer Support.
• Follow up your patient report easily and faster.

Our clinic portal allows you to:

• • Test Ordering
  • Report Download
  • Kit request
  • Clinical Data
  • Educational Content
  • Online Live Chat

  

MOSAIC HUMAN PREIMPLANTATION EMBRYOS AND THEIR DEVELOPMENTAL POTENTIAL IN A PROSPECTIVE NON-SELECTION CLINICAL TRIAL

• • Based in this clinical trial and according with emerging evidence, embryos with copy number variations between 30-50% (low mosaic grade) have equal reproductive potential as embryos with copy number variations less than 30% (reported as euploid).
  • Concordance studies have shown that biopsies with a low mosaic result most likely have euploid inner cell mas (ICM), the part of the embryo that will become the fetus.
  • The recently published PGDIS Position Statement on the transfer of low mosaic embryos states that these embryos should not be disregarded in terms of suitability for transfer.
  • This is the only non-selection study published based on its own internal validation of PGT-A using NGS, showing the potential outcome of transferring <50% mosaic embryos.

Learn More Link to Webinar

NON-INVASIVE PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDIES: AN UPDATE

• Aneuploidy is common among preimplantation human embryos used in assisted reproductive technology. Because an abnormal chromosome number can negatively affect outcomes, in vitro-fertilized embryos routinely undergo aneuploidy testing before transfer into the uterus. This testing typically involves an invasive trophectoderm biopsy of a blastocyst-stage embryo. However, emerging evidence indicates that, during in-vitro development, embryos secrete cell-free DNA into their culture medium; this phenomenon suggests the potential for an alternative, non-invasive assay for aneuploidy.
• We recently published a comprehensive update of (non-invasive preimplantation genetic testing for aneuploidies) in which we summarize all studies published to date, the main focus of the review is on the practical aspects of this new and promising technique.

• • Optimization of the embryo culture protocol
  • Feasibility on blastocysts that previously underwent assisted hatching and/or vitrification
  • Identifying and controlling sources of contamination
  • Defining optimal embryo culture time to yield the best concordance rates

Learn More Download Clinical Sheet

CHECK OUT OUR LATEST ENDOMETRIO PUBLICATIONS

Just recently, two new independent peer-reviewed studies have been published that demonstrate the benefit of the ERA test.

Only ERA, developed and patented by Igenomix in 2009, is backed by dozens of internal and external peer-reviewed publications.

In fact, other endometrial tests in the market use Igenomix publications to support their tests, though publications about ERA are unique and cannot be extrapolated to other endometrial tests.

• ERA in RIF patients levels their reproductive outcome to good prognosis patients. Liu et al. Front Physiol, 2022. Liu et al. Front Physiol, 2022. READ PAPER
• RIF patients who had a personalized embryo transfer according to ERA had a significatively better reproductive outcome. Jia et al. Medical Science Monitor, 2022. Jia et al. Medical Science Monitor, 2022. READ PAPER
• Endometrial microbiota composition is associated with reproductive outcome in infertile patients. Moreno et al. Microbiome Journal, 2022. READ PAPER

ENDOMETRIO IS A COMPLETE ANALYSIS OF ENDOMETRIAL HEALTH, INCLUDING THE ERA, EMMA AND ALICE TESTS

• Evaluates endometrial receptivity and determines the optimal moment for embryo transfer.
• Analyzes the endometrial microbiome for a more favorable reproductive prognosis.
• Detects bacteria that cause Chronic Endometritis and recommends the proper treatment.

Download Clinical Sheet